HADLIMA Drug Profile

✉ Email this page to a colleague

Summary for Tradename: HADLIMA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for HADLIMA

See drug prices for HADLIMA

Pharmacology for HADLIMA

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HADLIMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HADLIMA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HADLIMA Derived from Patent Text Search

No patents found based on company disclosures

HADLIMA Market Dynamics, Financial Trajectory, Patent Risk, and Biosimilar Competition

Last updated: November 3, 2026

HADLIMA is Samsung Bioepis' adalimumab biosimilar, marketed in the United States by Organon as adalimumab-bww. Its commercial opportunity is driven by the 2023 opening of the U.S. adalimumab market after Humira's core exclusivity period ended. HADLIMA entered a crowded field that includes Amgen's AMJEVITA, Sandoz's Hyrimoz, Boehringer Ingelheim's Cyltezo, Pfizer's Abrilada, and several other adalimumab biosimilars.

The product has a broad label covering rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. Its commercial position depends less on regulatory differentiation than on price, payer access, pharmacy substitution, interchangeability, supply reliability, and Organon's contracting scale.

What is HADLIMA and who markets adalimumab-bww?

HADLIMA is a biosimilar to AbbVie's Humira, whose active ingredient is adalimumab. Samsung Bioepis developed the product. Organon commercializes it in the United States under a collaboration with Samsung Bioepis.

Item	HADLIMA
Active ingredient	Adalimumab-bww
Reference product	Humira, adalimumab
Developer	Samsung Bioepis
U.S. commercial partner	Organon
FDA pathway	Section 351(k) biosimilar application
U.S. approval	July 2019
Dosage forms	Prefilled syringe and autoinjector presentations
Concentration	High-concentration, citrate-free formulation
Therapeutic areas	Immunology, dermatology, gastroenterology, rheumatology
U.S. launch	July 1, 2023 under AbbVie settlement terms
Interchangeability	FDA-designated interchangeable status for certain presentations, subject to product-specific labeling

The product's high-concentration, citrate-free presentation addresses two major Humira switching issues: injection volume and injection-site tolerability. Those attributes are important in patients and prescribers familiar with Humira's newer 40 mg/0.4 mL presentation.

When did HADLIMA lose exclusivity protection and enter the U.S. market?

HADLIMA did not receive a new biologic reference-product exclusivity period because it is a biosimilar. The relevant exclusivity belonged to Humira, whose 12-year U.S. reference-product exclusivity period expired in 2016. Patent settlements, rather than FDA exclusivity, delayed commercial biosimilar entry.

HADLIMA received FDA approval in 2019 but could not launch immediately because Organon and Samsung Bioepis settled patent litigation with AbbVie. The settlement permitted a U.S. launch beginning July 1, 2023.

U.S. exclusivity timeline

Date	Event
December 2002	Humira first received U.S. approval
2012	FDA's four-year biosimilar filing restriction for Humira expired
2016	Humira's 12-year reference-product exclusivity expired
July 2019	FDA approved HADLIMA
2019-2023	Patent litigation and settlement restrictions remained commercially relevant
July 1, 2023	Organon and Samsung Bioepis began U.S. HADLIMA commercialization
2023 onward	Multiple adalimumab biosimilars entered the U.S. market

The July 2023 entry date placed HADLIMA in the initial U.S. wave of adalimumab biosimilars rather than in a later second wave. That timing improved its contracting position but also exposed it to immediate competition from products backed by larger U.S. payer, hospital, or pharmacy networks.

What patents protect HADLIMA and what patents protected Humira?

HADLIMA itself is protected primarily through product development know-how, manufacturing processes, formulation work, regulatory exclusivity rules applicable to biosimilars, and contractual rights under the AbbVie settlement. It does not rely on a separate composition-of-matter patent covering adalimumab.

The principal patent risk came from AbbVie's Humira patent estate. AbbVie asserted a large portfolio of U.S. patents covering formulations, dosing regimens, manufacturing methods, and treatment methods. The most commercially important patents included late-expiring formulation and method-of-use claims, although individual patent validity and enforceability varied.

Patent category	Commercial relevance to HADLIMA
Adalimumab composition claims	Generally older and less important by the 2023 launch
High-concentration formulation claims	Relevant to product design and launch timing
Citrate-free formulation claims	Relevant to the modern Humira presentation
Dosing and treatment-method claims	Relevant to label strategy and prescribing practices
Manufacturing patents	Potentially relevant to process freedom to operate
Device and presentation claims	Relevant to autoinjector and syringe commercialization

AbbVie's patent strategy relied on portfolio depth rather than a single blocking patent. The practical result was a series of confidential or partially disclosed settlement agreements that established staggered launch dates for biosimilar manufacturers.

How strong is the patent estate around HADLIMA?

HADLIMA's direct patent estate is less important than its freedom-to-operate position against AbbVie. The product's strongest protection is commercial execution:

FDA approval and marketable presentation.
Access to Organon's U.S. contracting infrastructure.
Potential interchangeability benefits.
Samsung Bioepis' manufacturing and regulatory platform.
Settlement rights allowing commercial launch from July 2023.

The estate is therefore commercially defensible but not patent-protected in the manner of an innovative biologic. Revenue protection depends on contracts, payer placement, supply continuity, and switching economics.

What is the FDA and Orange Book status of HADLIMA?

HADLIMA is regulated as a biosimilar under the Public Health Service Act and is listed in the FDA's Purple Book, not the Orange Book. The Orange Book primarily identifies approved small-molecule drugs and related patent and exclusivity information. Biologic reference products and biosimilars are tracked through the Purple Book.

HADLIMA's status includes:

FDA approval under the 351(k) biosimilar pathway.
A label referencing Humira.
High-concentration and citrate-free presentations.
Interchangeability status for eligible presentations and indications under FDA labeling.
No separate 12-year biologic reference-product exclusivity period.

Interchangeability can improve pharmacy-level substitution, but the economic effect depends on state substitution laws, payer rules, pharmacy benefit design, and whether plans prefer automatic substitution or physician-directed switching.

Which companies are challenging Humira with biosimilars?

The U.S. adalimumab market has multiple competitors. The principal products include:

Company	Product	Strategic position
Organon/Samsung Bioepis	HADLIMA	Early launch, high-concentration and citrate-free positioning
Amgen	AMJEVITA	First U.S. adalimumab biosimilar launch; strong biologics infrastructure
Sandoz	Hyrimoz	Established biosimilar commercial platform
Boehringer Ingelheim	Cyltezo	Interchangeability and payer contracting relevance
Pfizer	Abrilada	Large pharmaceutical distribution and payer presence
Coherus BioSciences	Yusimry	Lower-cost commercial strategy
Celltrion	Yuflyma	High-concentration, citrate-free positioning
Fresenius Kabi	Idacio	Global biosimilar manufacturing platform
Viatris and Biocon Biologics	Hulio	International biosimilar experience

The market has two distinct segments. The first is the originator-like segment, which emphasizes high concentration, citrate-free delivery, established devices, and interchangeability. The second is the discount segment, which competes primarily through net price and payer contracts.

How does HADLIMA compare with Humira and competing biosimilars?

HADLIMA competes on clinical similarity and commercial convenience rather than on a novel mechanism. Its strongest product attributes are its high-concentration, citrate-free format and its connection to Samsung Bioepis' broader biosimilar portfolio.

Factor	HADLIMA	Humira	Other adalimumab biosimilars
Clinical mechanism	TNF inhibitor	TNF inhibitor	TNF inhibitor
Regulatory basis	Biosimilar	Reference biologic	Biosimilar
Price position	Negotiated discount	Originator net pricing	Broad range of discounts
Device familiarity	High	High	Varies
Interchangeability	Product- and presentation-specific	Reference product	Varies
Patient switching risk	Managed through education and support	Lowest for existing users	Varies by device and payer
Patent protection	No original-molecule estate	Extensive historical estate	Settlement and freedom-to-operate dependent

Clinical differentiation among approved adalimumab biosimilars is limited. Payers can therefore use formulary placement and rebates to force or encourage switching. Prescribers may continue to favor Humira or a familiar biosimilar when patients are stable, especially in inflammatory bowel disease and dermatology.

What is the financial trajectory for HADLIMA?

Organon does not disclose a standalone long-term revenue forecast for HADLIMA. Its financial performance is reported within the company's biosimilars portfolio and is affected by confidential gross-to-net discounts, inventory timing, tender contracts, and channel mix.

The product's financial trajectory has four stages:

2023: Launch and formulary establishment

HADLIMA entered the U.S. market in July 2023, the first full year in which the commercial opportunity became available. Initial revenue depended on launch inventory, payer contracts, specialty-pharmacy access, and the speed of switching from Humira.

The launch occurred under significant price pressure. AbbVie offered aggressive Humira rebates, while biosimilar manufacturers competed for preferred placement. This reduced the relationship between unit volume and reported revenue because higher prescription volume could be offset by lower net price.

2024-2025: Share capture and net-price compression

The second phase is likely to be defined by formulary consolidation. Payers generally have incentives to limit the number of preferred adalimumab products. Manufacturers with early contracts can retain volume, but later contracting cycles may demand deeper rebates.

HADLIMA's interchangeability and high-concentration presentation support access, but they do not guarantee preferred status. Organon's opportunity is strongest where its payer relationships and specialty-pharmacy channels produce recurring prescriptions.

2026 onward: Mature biosimilar economics

Mature revenue depends on whether the product becomes a durable preferred product or remains one of several interchangeable options. Unit volume may rise while revenue per unit falls. Manufacturing scale and procurement efficiency become more important than list price.

Financial drivers

Driver	Effect on HADLIMA
Preferred formulary placement	Increases volume and reduces dependence on physician-by-physician switching
Net price and rebates	Determines revenue quality and margin
Interchangeability	Can increase pharmacy substitution where legally permitted
High-concentration presentation	Supports conversion from modern Humira formulations
Specialty-pharmacy access	Important for chronic self-injected therapy
Manufacturing scale	Protects gross margin as prices decline
Patient-support programs	Reduces abandonment and improves persistence
Competitor count	Increases contracting pressure
Humira rebates	Can slow biosimilar conversion
International tender pricing	Expands volume but can compress unit economics

Organon's broader business model makes biosimilars strategically important because the company uses a portfolio of established products to offset loss of exclusivity across older medicines. HADLIMA contributes to that strategy, but its individual revenue cannot be evaluated independently from Organon's total biosimilars segment without product-level company disclosure.

What generic entry risks exist for HADLIMA?

Traditional generic entry is not the principal risk because HADLIMA is itself a biosimilar. The relevant risks are biosimilar substitution, payer exclusion, price erosion, and manufacturing competition.

The highest-risk scenario is a preferred-product market in which one or two adalimumab biosimilars receive dominant formulary status and other products are relegated to nonpreferred tiers. In that environment, HADLIMA could retain prescriptions but lose net price.

A second risk is originator defense. AbbVie can preserve Humira volume through rebates, patient-support programs, contracting, and physician familiarity. Biosimilar uptake can therefore remain below the level implied by list-price discounts.

A third risk is operational. Biologics require validated manufacturing, cold-chain distribution, device reliability, and continuous regulatory compliance. A supply interruption can cause permanent payer and prescriber displacement.

What patent litigation and settlement agreements affect HADLIMA?

HADLIMA's U.S. entry was governed by settlement arrangements between AbbVie, Samsung Bioepis, and Organon. Those arrangements permitted launch on July 1, 2023 and limited the need for a final validity ruling before market entry.

The settlements reduced immediate injunction risk but did not remove commercial competition. They also illustrate the distinction between legal launch freedom and economic freedom. A biosimilar can enter legally while facing intense contracting pressure from the reference-product sponsor and competing biosimilar manufacturers.

No conventional Paragraph IV pathway applies to HADLIMA in the same manner as a small-molecule ANDA. Biosimilar applicants use the 351(k) framework and the Biologics Price Competition and Innovation Act patent-information and litigation procedures. The relevant patent dispute process is often described as the "patent dance," although participation and litigation strategy can vary.

What geographic markets are important for HADLIMA?

The United States is the highest-value market because Humira generated substantial U.S. revenue and biosimilar substitution can produce large savings. Europe has had adalimumab biosimilar competition for several years, making the commercial environment more mature and price-sensitive.

Samsung Bioepis and Organon also operate across international markets, subject to local approvals, tender systems, reimbursement decisions, and country-specific patent rights. European tender markets can generate significant volume but lower prices. Emerging markets may offer growth but have lower reimbursement and less predictable biologic access.

U.S. performance is therefore the main determinant of HADLIMA's financial trajectory, while international markets provide portfolio scale and manufacturing utilization.

Key Takeaways

HADLIMA is Samsung Bioepis' adalimumab-bww biosimilar marketed by Organon.
FDA approval occurred in July 2019, but U.S. commercial launch began July 1, 2023 under AbbVie settlement terms.
The product competes in a crowded market with AMJEVITA, Hyrimoz, Cyltezo, Abrilada, Yusimry, Yuflyma, and other adalimumab biosimilars.
High-concentration, citrate-free delivery and interchangeability support commercialization but do not eliminate payer-driven price competition.
HADLIMA is tracked in the FDA Purple Book, not the Orange Book.
Its financial trajectory depends on formulary placement, net pricing, pharmacy substitution, patient switching, and manufacturing scale.
Organon's public reporting does not provide a dependable standalone long-term revenue forecast for HADLIMA.
The central commercial risk is net-price erosion in a multi-biosimilar market, not conventional generic substitution.
AbbVie's patent settlements reduced launch uncertainty but did not protect HADLIMA from contracting and competitive pressure.

FAQs About HADLIMA Market Opportunity and Patent Risk

Is HADLIMA interchangeable with Humira?

HADLIMA has FDA-designated interchangeable status for eligible presentations and indications under its approved labeling. Actual substitution depends on state law, payer policy, pharmacy practice, and prescription instructions.

Does HADLIMA have its own patent protection?

HADLIMA does not have a new adalimumab composition-of-matter patent comparable to an innovative biologic. Its commercial protection comes from regulatory approval, manufacturing know-how, formulation and device development, supply capabilities, and settlement-based freedom to operate.

How much cheaper is HADLIMA than Humira?

The discount varies by list price, payer contract, rebate, channel, and presentation. Net prices are generally confidential, and a lower list price does not necessarily equal a lower net price for every payer or patient.

Can patients switch directly from Humira to HADLIMA?

Patients can be switched when clinically appropriate under physician and payer protocols. The decision depends on disease control, indication, device preference, reimbursement, and whether the product is being used under interchangeable-substitution rules.

Will HADLIMA revenue increase as Humira declines?

Not necessarily on a one-for-one basis. HADLIMA can gain unit volume while reported revenue and margin decline because multiple biosimilars and AbbVie rebates create substantial net-price pressure.

References

AbbVie Inc. (2024). 2023 annual report. AbbVie.
Food and Drug Administration. (2019). BLA 761071: HADLIMA (adalimumab-bww) approval letter and prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
Organon & Co. (2024). 2023 annual report. Organon & Co.
Organon & Co. (2025). 2024 annual report. Organon & Co.
Samsung Bioepis. (2023). HADLIMA (adalimumab-bww) U.S. product information. Samsung Bioepis.
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, Title VII. 124 Stat. 119.

More… ↓

⤷ Start Trial